Flow Pharma FlowVax™ Peptide Vaccine for COVID-19
Flow Pharma is developing FlowVax COVID-19, which is being designed to generate a robust immune response to protect individuals against infection with SARS-CoV-2 by targeting parts of the virus least likely to mutate. FlowVax COVID-19 is a room temperature stable dry powder not requiring refrigeration, and is being developed for delivery by injection or inhalation.
FlowVax COVID-19 is entering primate testing April 2020 at the University of Texas Medical Branch / Galveston National Laboratory.
FlowVax COVID-19 may succeed where traditional vaccines sometimes fail, because it can more easily target regions on the virus least able to mutate to escape attack.